Agios Pharmaceuticals’ (NASDAQ:AGIO) “Buy” Rating Reaffirmed at SunTrust Banks, Inc.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)‘s stock had its “buy” rating restated by stock analysts at SunTrust Banks, Inc. in a report issued on Tuesday. They presently have a $80.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $68.00. SunTrust Banks, Inc.’s target price would indicate a potential upside of 34.43% from the stock’s current price.
Several other equities analysts also recently commented on AGIO. Leerink Swann upgraded shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $50.00 to $80.00 in a research note on Wednesday, August 2nd. Janney Montgomery Scott reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, August 1st. Canaccord Genuity set a $90.00 price objective on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 13th. Finally, Oppenheimer Holdings, Inc. set a $75.00 price objective on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, June 11th. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $68.67.
Agios Pharmaceuticals (NASDAQ AGIO) traded down 2.54% on Tuesday, hitting $59.51. The stock had a trading volume of 1,058,869 shares. The stock’s market cap is $2.87 billion. The firm’s 50 day moving average price is $55.14 and its 200-day moving average price is $50.99. Agios Pharmaceuticals has a 12 month low of $35.84 and a 12 month high of $67.74.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by $0.21. The business had revenue of $11.30 million during the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. The business’s revenue was up 62.1% on a year-over-year basis. During the same quarter last year, the firm earned ($1.47) EPS. On average, analysts forecast that Agios Pharmaceuticals will post ($6.43) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/08/agios-pharmaceuticals-nasdaqagio-buy-rating-reaffirmed-at-suntrust-banks-inc.html.
In other news, CEO David P. Schenkein sold 27,000 shares of the stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $59.95, for a total value of $1,618,650.00. Following the completion of the sale, the chief executive officer now owns 3,000 shares of the company’s stock, valued at $179,850. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David P. Schenkein sold 3,000 shares of the stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $50.02, for a total transaction of $150,060.00. Following the completion of the sale, the chief executive officer now directly owns 1,100 shares of the company’s stock, valued at approximately $55,022. The disclosure for this sale can be found here. Insiders have sold 79,120 shares of company stock worth $4,557,207 in the last three months. Insiders own 10.55% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in AGIO. Swiss National Bank raised its position in shares of Agios Pharmaceuticals by 3.4% in the first quarter. Swiss National Bank now owns 55,360 shares of the biopharmaceutical company’s stock valued at $3,233,000 after buying an additional 1,800 shares in the last quarter. Spark Investment Management LLC raised its position in shares of Agios Pharmaceuticals by 139.9% in the second quarter. Spark Investment Management LLC now owns 84,700 shares of the biopharmaceutical company’s stock valued at $4,357,000 after buying an additional 49,400 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Agios Pharmaceuticals by 8.3% in the first quarter. Geode Capital Management LLC now owns 263,899 shares of the biopharmaceutical company’s stock valued at $15,410,000 after buying an additional 20,336 shares in the last quarter. Clear Harbor Asset Management LLC bought a new position in shares of Agios Pharmaceuticals during the first quarter valued at $270,000. Finally, Ameriprise Financial Inc. raised its position in shares of Agios Pharmaceuticals by 8.5% in the first quarter. Ameriprise Financial Inc. now owns 41,029 shares of the biopharmaceutical company’s stock valued at $2,397,000 after buying an additional 3,215 shares in the last quarter. 84.53% of the stock is owned by institutional investors and hedge funds.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.